How a patented combination of fatty acids and PEA was developed to support nerve health in people experiencing chemotherapy-induced peripheral neuropathy.
CIPN is a common, often persistent side effect of cancer treatment. It happens when chemotherapy damages peripheral nerves, producing tingling, burning, numbness, balance changes, and difficulty with everyday tasks. For many people, these symptoms continue long after treatment ends.
Peripheral nerves carry the signals that let you feel, move, balance, and sense the world. When that signaling is disrupted, the impact reaches far beyond physical discomfort — it touches confidence, independence, and quality of life.
Specific fatty acids are essential building blocks of the myelin sheath — the insulating layer that allows nerves to transmit signals quickly and accurately. Supporting fatty acid availability supports the structural raw materials of healthy nerves.
Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide that the body produces in response to stress or injury. PEA has been studied for its role in supporting healthy inflammatory balance and nerve cell function.
The STEFANO study evaluated the patented fatty acid + PEA formulation behind Novilora in 146 patients experiencing CIPN after cancer treatment. Researchers observed improvements and stabilization of sensory and motor neuropathy symptoms following three months of use.
Across the published evidence base, the formulation has been associated with patient-reported improvements in comfort and function. This research informs how Novilora is designed and how it is intended to be used over a three-month evaluation period.
Frequently asked
The Research Center contains the full clinical write-up, FAQ knowledge base, and downloadable studies.